Last Updated : November 22, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Kuvan | Sapropterin dihydrochloride | Phenylketonuria (PKU) | Do not list | Complete | ||
Kuvan | Sapropterin dihydrochloride | Phenylketonuria | N/A | Complete | ||
Kuvan | Sapropterin dihydrochloride | Phenylketonuria (PKU) | Reimburse with clinical criteria and/or conditions | Complete | ||
Kymriah | tisagenlecleucel | Relapsed or refractory follicular lymphoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Kynmobi | apomorphine hydrochloride | Parkinson’s Disease | Withdrawn | |||
Kynmobi | apomorphine hydrochloride | Parkinson’s disease | Reimburse with clinical criteria and/or conditions | Complete | ||
Kyprolis | Carfilzomib | Multiple Myeloma (relapsed) | Reimburse with clinical criteria and/or conditions | Complete | ||
Kyprolis (with lenalidomide) | Carfilzomib (with lenalidomide) | Multiple Myeloma | Reimburse with clinical criteria and/or conditions | Complete | ||
Lancora | Ivabradine | Heart failure, NYHA class II or III | Reimburse with clinical criteria and/or conditions | Complete | ||
Lantus | Insulin glargine (rDNA origin) | Diabetes mellitus, Type 1 & 2 | Do not list | Complete | ||
Lantus | Insulin glargine (rDNA origin) | Diabetes mellitus, Type 1 & 2 | Do not list | Complete | ||
Lantus | Insulin glargine (rDNA origin) | Diabetes mellitus, Type 1 & 2 | N/A | Complete | ||
Lapelga | Pegfilgrastim | Febrile neutropenia | N/A | Complete | ||
Lartruvo | Olaratumab | Advanced Soft Tissue Sarcoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Latuda | lurasidone | Bipolar I disorder | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | ||
Latuda | Lurasidone | Schizophrenia | Do not list | Complete | ||
Latuda | Lurasidone | Schizophrenia | List with criteria/condition | Complete | ||
Lazcluze and Rybrevant | lazertinib and amivantamab | Locally advanced or metastatic non-small cell lung cancer (NSCLC) | Pending | |||
Ledaga | chlormethine hydrochloride | T-cell lymphoma | Do not reimburse | Complete | ||
Lemtrada | Alemtuzumab | Multiple sclerosis, relapsing-remitting | Withdrawn | |||
Lemtrada | Alemtuzumab | Multiple sclerosis, relapsing-remitting | List with criteria/condition | Complete | ||
Lenvima | Lenvatinib | Renal Cell Carcinoma (RCC) | Do not reimburse | Complete | ||
Lenvima | Lenvatinib | Hepatocellular Carcinoma (HCC) | Reimburse with clinical criteria and/or conditions | Complete | ||
Lenvima | Lenvatinib | Differentiated Thyroid Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Lenvima and Keytruda | lenvatinib and pembrolizumab | advanced or metastatic renal cell carcinoma | Reimburse with clinical criteria and/or conditions | Complete |